Cassidy Bio

In July 2025, Cassidy Bio announced the successful closure of an $8 million seed funding round, a significant event intended to propel its preclinical research and the development of its next-generation therapeutic platforms. This capital injection is earmarked for enhancing laboratory facilities and expanding its scientific team. The financing was supported by a syndicate of investors including 10D, Ahren Innovation Capital, AION Labs, Amiti Ventures, and Israel Biotech Fund. Prior to this, the company was part of an accelerator/incubator program with AION Labs.

The company's primary offering is a predictive platform designed for the intricate process of guide RNA (gRNA) design, which is critical for the precision of CRISPR systems. This AI-driven tool provides rapid gRNA ranking and comprehensive on/off-target predictions across various editing technologies and cell types. By identifying potential genotoxicity and other risks early on, the platform aims to reduce adverse outcomes in clinical applications and streamline decision-making for its partners. The company's leadership includes Dr. Ayal Hendel, a recognized expert in genome editing and gene therapy from Bar-Ilan University with postdoctoral training at Stanford University, and Dr. Yaron Shmueli, who brings over 25 years of experience in AI and machine learning, including roles at Meta Platforms.